The BAF Complex Inhibitor Pyrimethamine Reverses HIV-1 Latency in People with HIV-1 on Antiretroviral Therapy

28 people living with HIV-1 on suppressive antiretroviral therapy were randomized to receive pyrimethamine, valproic acid, both, or no intervention for 14 days, in order to investigate the impact of the BAF complex inhibitor pyrimethamine of the latent HIV-1 reservoir.